New CAR t therapy targets tough lung cancers in first human trial
Disease control
Not yet recruiting
This early-phase study tests a new treatment called ML261 for people with small cell lung cancer or certain neuroendocrine cancers that have come back or stopped responding to standard therapy. ML261 uses a patient's own immune cells, modified to better recognize and attack cance…
Phase: PHASE1 • Sponsor: Moonlight Bio, Inc • Aim: Disease control
Last updated May 26, 2026 10:04 UTC